Physician profile
Ajith Kumar
NPI 1609952381
$671.72
in general payments reported to CMS, 2019-2025
10 companies · $56.61 in 2025
The $56.61 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.95 · 2020: $145 · 2021: $121 · 2022: $103 · 2023: $151 · 2025: $56.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $177.48 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $143.15 | 2022-2025 | |
| Novo Nordisk INC | $119.08 | 2019-2023 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $64.47 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $59.43 | 2020-2022 | |
| Vifor Pharma, INC. | $32.10 | 2019-2025 | Veltassa |
| Pfizer INC. | $28.71 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.95 | 2023 | Purified Cortrophin Gel |
| Amgen INC. | $15.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajith Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.